More Articles

EMA approval for Teva’s long-acting recombinant G-CSF Biosimilars/News | Posted 23/08/2013

The European Medicines Agency (EMA) has granted marketing authorization for a new long-acting filgrastim – Lonquex (XM22 lipegfilgrastim) – to prevent chemotherapy-induced neutropenia in cancer pat...

FDA increases generic drug user fees in 2014 Generics/General | Posted 23/08/2013

FDA has increased the amount that generics manufacturers will have to pay to register their finished drug formulation (FDF) facilities by more than US$40,000 for 2014 compared to 2013.

Eli Lilly attempts to further delay Alimta generics Generics/News | Posted 23/08/2013

Pharma giant Eli Lilly was scheduled to be in court on 19 August 2013 to defend another of its patents on its blockbuster lung cancer drug Alimta (pemetrexed).

Fresenius Kabi sets up generics joint venture in Indonesia Pharma News | Posted 23/08/2013

Fresenius Kabi, the generics unit of healthcare giant Fresenius, announced on 19 August 2013 that it had set up a joint venture with Indonesia-based PT Soho Global Health, acquiring a 51% share in...

Pfizer’s US$2.15 billion settlement with Teva and Sun Pharma Generics/News | Posted 23/08/2013

Pfizer announced in June a US$2.15 billion settlement with Teva and Sun Pharmaceutical Industries (Sun Pharma) for patent-infringement damages resulting from unlawful launches of generic Protonix (...

How regional sickness funds in Austria encourage more rational prescribing Generics/Research | Posted 16/08/2013

In Austria, as in other EU countries, rational use of medicines is high on the healthcare agenda. According to WHO, use of generic medicines help reduce costs incurred by public payers and is a way...

Assessment of efficacy and safety of biosimilars in rheumatology Biosimilars/Research | Posted 16/08/2013

During the last decade, the availability of biological therapies has revolutionized the treatment of rheumatoid arthritis. Biologicals, unlike small-molecule chemical drugs, are extremely complex m...

Implications of the changes in venlafaxine utilization in Sweden following generics Generics/Research | Posted 16/08/2013

Godman and co-authors review the changes in the utilization of venlafaxine post generics. This includes the limited influence on utilization post generics with no specific demand-side measures. Thi...